Myriad Genetics Inc. has announced the upcoming limited clinical launch of its Precise MRD™ (molecular residual disease) assay, transitioning from research-use-only to clinical use in March 2026. The initial rollout will focus on breast cancer, with expansion to colorectal and renal cancers later in the year, and potential inclusion of ovarian and endometrial cancers in 2027 and beyond. Interim data from the MONITOR-Breast study, presented at the 2025 San Antonio Breast Cancer Symposium and published in The Lancet Oncology, demonstrated 93% baseline sensitivity in detecting circulating tumor DNA (ctDNA) in breast cancer patients, with high detection rates across various stages and subtypes. Additional findings were also presented at the 2026 ASCO Gastrointestinal Cancers Symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9642956-en) on January 27, 2026, and is solely responsible for the information contained therein.